Moneycontrol PRO
HomeNewscoronavirusSputnik V | Five quick facts about the Russian COVID-19 vaccine that received expert panel nod

Sputnik V | Five quick facts about the Russian COVID-19 vaccine that received expert panel nod

The vaccine has a proven efficacy rate of 91.5 percent, which is the highest after the candidates of Moderna Inc and Pfizer-BioNTech.

April 12, 2021 / 17:34 IST
Representative image (Reuters)

Sputnik V, the COVID-19 vaccine developed by Moscow-based Gamaleya Institute, was on April 12 recommended for emergency use by the Subject Expert Committee (SEC) - a top advisory body linked to the Drug Controller General of India (DCGI).

Here are five quick facts to know about the Russian vaccine against coronavirus.

Named after the first space satellite of erstwhile Soviet Union, Sputnik V was approved by the regulators in Russia back in August 2020. The vaccine is based on a weakened COVID-19 virus delivering parts of a pathogen that triggers an immune response in the body.

The vaccine has a proven efficacy rate of 91.5 percent, which is the highest after the candidates of Moderna Inc and Pfizer-BioNTech.

The cost of Sputnik V, in the international market, is $10 per shot. The vaccine is required to be taken in two doses. It can be stored in dry form at temperature ranging from 2 to 8 degrees.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The Russian Direct Investment Fund (RDIF) had partnered with Dr Reddy's in September 2020 for completion of phase 3 trials in India. The Panacea Biotec, a pharmaceutical firm headquartered in India, said it would produce 100 million doses of Sputnik V annually.

The phase 3 trials of the vaccine are currently underway in UAE, India, Venezuela and Belarus. In India, nearly 1,600 persons were enrolled for the trials, aged between 18 and 99.

Moneycontrol News
first published: Apr 12, 2021 04:13 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347